CDXS Quote, Financials, Valuation and Earnings

Artiva Biotherapeutics has a net margin of -160.84% compared to Codexis's net margin of -5562.95%. Codexis's return on equity of -79.15% beat Artiva Biotherapeutics's return on equity of --.

Codexis has a consensus price target of $6.86, signalling upside risk potential of 35.73%. On the other hand Artiva Biotherapeutics has an analysts' consensus of -- which suggests that it could grow by 91.27%. Given that Artiva Biotherapeutics has higher upside potential than Codexis, analysts believe Artiva Biotherapeutics is more attractive than Codexis.

Codexis has a beta of 2.155, which suggesting that the stock is 115.515% more volatile than S&P 500. In comparison Artiva Biotherapeutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Codexis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Artiva Biotherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis pays -- of its earnings as a dividend. Artiva Biotherapeutics pays out -- of its earnings as a dividend.

Codexis quarterly revenues are $12.8M, which are larger than Artiva Biotherapeutics quarterly revenues of $251K. Codexis's net income of -$20.6M is lower than Artiva Biotherapeutics's net income of -$14M. Notably, Codexis's price-to-earnings ratio is -- while Artiva Biotherapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis is 5.77x versus 48.72x for Artiva Biotherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Generation Bio has a net margin of -160.84% compared to Codexis's net margin of -202.71%. Codexis's return on equity of -79.15% beat Generation Bio's return on equity of -92.44%.

Codexis has a consensus price target of $6.86, signalling upside risk potential of 35.73%. On the other hand Generation Bio has an analysts' consensus of $7.50 which suggests that it could grow by 530.25%. Given that Generation Bio has higher upside potential than Codexis, analysts believe Generation Bio is more attractive than Codexis.

Codexis has a beta of 2.155, which suggesting that the stock is 115.515% more volatile than S&P 500. In comparison Generation Bio has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Codexis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Generation Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis pays -- of its earnings as a dividend. Generation Bio pays out -- of its earnings as a dividend.

Codexis quarterly revenues are $12.8M, which are larger than Generation Bio quarterly revenues of $7.6M. Codexis's net income of -$20.6M is lower than Generation Bio's net income of -$15.3M. Notably, Codexis's price-to-earnings ratio is -- while Generation Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis is 5.77x versus 4.26x for Generation Bio. Usually stocks with elevated PS ratios are considered overvalued.

Maravai LifeSciences Holdings has a net margin of -160.84% compared to Codexis's net margin of -151.9%. Codexis's return on equity of -79.15% beat Maravai LifeSciences Holdings's return on equity of -29.18%.

Codexis has a consensus price target of $6.86, signalling upside risk potential of 35.73%. On the other hand Maravai LifeSciences Holdings has an analysts' consensus of $9.07 which suggests that it could grow by 68.8%. Given that Maravai LifeSciences Holdings has higher upside potential than Codexis, analysts believe Maravai LifeSciences Holdings is more attractive than Codexis.

Codexis has a beta of 2.155, which suggesting that the stock is 115.515% more volatile than S&P 500. In comparison Maravai LifeSciences Holdings has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Codexis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Maravai LifeSciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis pays -- of its earnings as a dividend. Maravai LifeSciences Holdings pays out -- of its earnings as a dividend.

Codexis quarterly revenues are $12.8M, which are smaller than Maravai LifeSciences Holdings quarterly revenues of $65.2M. Codexis's net income of -$20.6M is higher than Maravai LifeSciences Holdings's net income of -$99M. Notably, Codexis's price-to-earnings ratio is -- while Maravai LifeSciences Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis is 5.77x versus 2.63x for Maravai LifeSciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

OraSure Technologies has a net margin of -160.84% compared to Codexis's net margin of -11.29%. Codexis's return on equity of -79.15% beat OraSure Technologies's return on equity of 2.69%.

Codexis has a consensus price target of $6.86, signalling upside risk potential of 35.73%. On the other hand OraSure Technologies has an analysts' consensus of $6.00 which suggests that it could grow by 64.84%. Given that OraSure Technologies has higher upside potential than Codexis, analysts believe OraSure Technologies is more attractive than Codexis.

Codexis has a beta of 2.155, which suggesting that the stock is 115.515% more volatile than S&P 500. In comparison OraSure Technologies has a beta of 0.034, suggesting its less volatile than the S&P 500 by 96.598%.

Codexis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OraSure Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Codexis pays -- of its earnings as a dividend. OraSure Technologies pays out -- of its earnings as a dividend.

Codexis quarterly revenues are $12.8M, which are smaller than OraSure Technologies quarterly revenues of $39.9M. Codexis's net income of -$20.6M is lower than OraSure Technologies's net income of -$4.5M. Notably, Codexis's price-to-earnings ratio is -- while OraSure Technologies's PE ratio is 24.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Codexis is 5.77x versus 1.21x for OraSure Technologies. Usually stocks with elevated PS ratios are considered overvalued.